HRP20140929T1 - Antitumorska svojstva no-modificiranih inhibitora proteaze - Google Patents
Antitumorska svojstva no-modificiranih inhibitora proteaze Download PDFInfo
- Publication number
- HRP20140929T1 HRP20140929T1 HRP20140929AT HRP20140929T HRP20140929T1 HR P20140929 T1 HRP20140929 T1 HR P20140929T1 HR P20140929A T HRP20140929A T HR P20140929AT HR P20140929 T HRP20140929 T HR P20140929T HR P20140929 T1 HRP20140929 T1 HR P20140929T1
- Authority
- HR
- Croatia
- Prior art keywords
- protease inhibitors
- compounds
- modified protease
- antitumor properties
- saquinavir
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 4
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 229910017604 nitric acid Inorganic materials 0.000 claims 2
- 229960001852 saquinavir Drugs 0.000 claims 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims 2
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960000884 nelfinavir Drugs 0.000 claims 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (5)
1. Esteri inhibitora HIV proteaze s dušičnom kiselinom, naznačeni time što se inhibitori HIV proteaze biraju između sakvinavira, ritonavira ili nelfinavira.
2. Ester sakvinavira s dušičnom kiselinom u skladu s patentnim zahtjevom 1, naznačen time što ima formulu I
[image]
,
njegove netoksične soli, solvati, polimorfni ili/i kristalni oblici.
3. Farmaceutski pripravci, naznačeni time što sadrže spojeve u skladu s patentnim zahtjevima 1-2, u smjesi s pogodnom podlogom odnosno pomoćnim tvarima.
4. Spojevi u s kladu s patentnim zahtjevima 1-2, naznačeni time što su namijenjeni upotrebi u liječenju tumora ili infekcija HIV-om.
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačeni time što su namijenjeni upotrebi u liječenju pacijenata koji boluju od tumora i/ili infekcija HIV-om, što se sastoji u primjeni na navedenim pacijentima djelotvorne količine navedenih spojeva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8555508P | 2008-08-01 | 2008-08-01 | |
| PCT/EP2009/005526 WO2010012466A1 (en) | 2008-08-01 | 2009-07-30 | Antitumor properties of no modified protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140929T1 true HRP20140929T1 (hr) | 2014-12-05 |
Family
ID=41139301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140929AT HRP20140929T1 (hr) | 2008-08-01 | 2014-09-29 | Antitumorska svojstva no-modificiranih inhibitora proteaze |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8563578B2 (hr) |
| EP (1) | EP2306995B1 (hr) |
| JP (1) | JP2011529864A (hr) |
| CN (1) | CN102131501A (hr) |
| DK (1) | DK2306995T3 (hr) |
| ES (1) | ES2509493T3 (hr) |
| HR (1) | HRP20140929T1 (hr) |
| PL (1) | PL2306995T3 (hr) |
| PT (1) | PT2306995E (hr) |
| WO (1) | WO2010012466A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102260243B (zh) * | 2011-06-09 | 2013-08-14 | 沈阳亿灵医药科技有限公司 | 沙奎那韦琥珀酸半酯盐及其制剂 |
| EP2922545B1 (en) * | 2012-11-20 | 2016-09-21 | Onconox ApS | Saquinavir-no for immunomodulation |
| CN107281462A (zh) * | 2017-08-21 | 2017-10-24 | 滨州医学院 | 沙奎拉韦减轻伊立替康毒性的医药新用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1311923B1 (it) | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
| IT1314184B1 (it) | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
| US20090131342A1 (en) * | 2004-01-22 | 2009-05-21 | Nitromed, Inc. | Nitrosated and/or nitrosylated compounds, compositions and methods of use |
| EP1789091B1 (en) | 2004-08-26 | 2010-08-25 | Piramal Life Sciences Limited | Prodrugs containing novel bio-cleavable linkers |
-
2009
- 2009-07-30 ES ES09777548.0T patent/ES2509493T3/es active Active
- 2009-07-30 WO PCT/EP2009/005526 patent/WO2010012466A1/en active Application Filing
- 2009-07-30 DK DK09777548.0T patent/DK2306995T3/da active
- 2009-07-30 US US13/056,696 patent/US8563578B2/en active Active
- 2009-07-30 PT PT97775480T patent/PT2306995E/pt unknown
- 2009-07-30 EP EP09777548.0A patent/EP2306995B1/en active Active
- 2009-07-30 PL PL09777548T patent/PL2306995T3/pl unknown
- 2009-07-30 JP JP2011520378A patent/JP2011529864A/ja active Pending
- 2009-07-30 CN CN2009801303244A patent/CN102131501A/zh active Pending
-
2014
- 2014-09-29 HR HRP20140929AT patent/HRP20140929T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8563578B2 (en) | 2013-10-22 |
| DK2306995T3 (da) | 2014-10-20 |
| ES2509493T3 (es) | 2014-10-17 |
| WO2010012466A8 (en) | 2010-04-22 |
| US20110195939A1 (en) | 2011-08-11 |
| PL2306995T3 (pl) | 2014-12-31 |
| JP2011529864A (ja) | 2011-12-15 |
| EP2306995B1 (en) | 2014-07-30 |
| PT2306995E (pt) | 2014-10-06 |
| EP2306995A1 (en) | 2011-04-13 |
| CN102131501A (zh) | 2011-07-20 |
| WO2010012466A1 (en) | 2010-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500375A1 (en) | Nep inhibitors for treating diseases characterized by atrial enlargemenet or remodeling | |
| EA201101243A1 (ru) | 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств | |
| SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| BRPI0917444A2 (pt) | composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc | |
| WO2008063300A8 (en) | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | |
| WO2013188792A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| ZA200806778B (en) | N-Hydroxyacrylamide compounds | |
| RU2008108516A (ru) | 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ | |
| NZ619076A (en) | Isoxazolines as inhibitors of fatty acid amide hydrolase | |
| EA201890771A1 (ru) | Соли и твердые формы монобактамного антибиотика | |
| EA201100863A1 (ru) | Фармацевтическая композиция, включающая диклофенак и сложный эфир гидроксижирной кислоты и полиоксиалкилена | |
| CY1120852T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας | |
| EA201492127A1 (ru) | Пролекарственные производные (е)-n-метил-n-((3-метилбензофуран-2-ил)метил)-3-(7-оксо-5,6,7,8-тетрагидро-1,8-нафтиридин-3-ил)акриламида | |
| ATE536172T1 (de) | Ezetimibzusammensetzungen | |
| EP2137175A4 (en) | NOVEL PHENANTHRENNEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF METABOLIC SYNDROME INVOLVING DISEASES | |
| DK1608346T3 (da) | Lægemiddeltilförselssammensætninger af alfa-hydroxysyreester og fremgangsmåder til anvendelse heraf | |
| WO2016199076A3 (en) | Polymorphic forms of afatinib free base and afatinib dimaleate | |
| HRP20201932T4 (hr) | Stimulatori / aktivatori topive gvanilat-ciklaze u kombinaciji s nep-inhibitorom i/ili angiotenzin aii-antagonistom i njihova uporaba | |
| HRP20140929T1 (hr) | Antitumorska svojstva no-modificiranih inhibitora proteaze | |
| PH12017501444A1 (en) | (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | |
| CA2794655A1 (en) | Method for treating schizophrenia and related diseases | |
| WO2011089126A3 (en) | Novel retigabine composition | |
| EP2212325A4 (en) | 2-ARYLMETHYLAZETIDINCARBAPENEM-3-CARBOXYLENE DERTERIVATE OR SALT, METHOD FOR THE PRODUCTION THEREOF AND THEREOF COMPRISING PHARMACEUTICAL COMPOSITION | |
| PH12017500859A1 (en) | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof | |
| FR2940116B1 (fr) | Formulation pour l'administration d'hypolipemiant par voie trans-muqueuse buccale |